LAG3 and head and neck squamous cell carcinoma: Furthermore, a randomized phase IIb trial is currently in progress to study the effectiveness of Eftilagimod alpha (a soluble LAG‐3 protein) in combination with pembrolizumab as a second‐line treatment for patients with R/M HNSCC [90].